



INVEST LIKE A PRO, WITH THE PROS!





Why does Stanley Cup winner *Bryce Salvador* swear by *Eyecarrot Innovations'* Binovi vision therapy technology product.

Find out in our [new podcast](#).

Details below in the Daily Update.

www.capitalideasmmedia.com

Morning Need to Know

Getting you ready for your investing day

February 1, 2019

Written & compiled by Mark Bunting, Publisher,
Capital Ideas Media



CANADIAN ANALYSTS' CALLS

Mullen Group (TSX:MTL). Raymond James upgrades to "outperform" and keeps the target at \$15.60 (Canadian) saying it sees a "*rare value-based entry point*".

Aecon (TSX:ARE) Industrial Alliance Securities analyst Neil Linsdell says his favourite stocks in the Canadian consumer and industrial products sector are "*under-appreciated*" names.

He has four top picks including ARE, which he gives a "strong buy" and a price target of \$23 (Canadian).

Aecon was our cover story on May 29 last year when it was trading around \$15. It closed Thursday at \$18.27.

Linsdell's other top picks are:

GDI Integrated Facility Services (TSX:GDI) with a “buy” and a \$23 target.

Intertape Polymer Group (TSX:ITP) with a “buy” and a \$26 target.

Enwave (TSXV:ENW) “buy” and a \$2.35 target.

Eldorado Gold (TSX:ELD). National Bank has raised the price target to \$8 from \$4.75 saying the company's decision to shelve its Kisladag project is positive. ELD's shares surged 27% on Thursday to close at \$4.92.

Cormark Securities elevates ELD to "buy" and moves the target to \$8 from \$5.40.

Organigram (TSXV:OGI). Mackie Research increases the price target to \$10.75 from \$10, implying a 44% 12-month return, and maintains a "buy" rating after the company released its quarterly earnings results.

Baytex (TSX:BTE). CIBC has reduced the price targets and cash flow per share (CFPS) estimates for a slew of Canadian energy companies including Baytex, which sees its target dropped to \$4.25 from \$5.25, and its 2019 CFPS forecast cut to \$1.31 from \$1.42.



U.S. ANALYSTS' CALLS

Amazon.com (NASDAQ:AMZN) has had its price target cut by a number of research houses including Macquarie, which reduces the target to \$1,850 (U.S.) from \$2,100. See below for more on Amazon's earnings.

MasterCard (NYSE:MA). Oppenheimer hikes the target to \$242 from \$221.

STOCKS THAT MAY MOVE

NorthWest Healthcare Properties REIT (TSX:NWH.UN)

is buying 11 freehold hospital property assets from Australia's Healthscope for about \$1.2 billion (Canadian) as part of a sale and leaseback deal. NorthWest will wind up with as much as a 30% ownership stake in the properties.

Brookfield Asset Management (TSX:BAM.A;NYSE:BAM).

And NorthWest will likely be dealing regularly with Brookfield because it's appeared to have won a takeover battle for Healthscope, which has recommended a bid by BAM worth \$4. billion.

Tecsys (TSX:TCS) is buying PCSYS A/S, a

Danish technology company, for nearly \$14 million.

Teck Resources (TSX:TECK.B;NYSE:TECK)

has issued a profit warning saying Q4 earnings will be about \$0.30 a share lower than the \$1.10 expected in part because of "*disappointing*" business in its energy division.

Amazon.com (NASDAQ:AMZN) is down in pre-market trading after the e-commerce giant beat estimates with record-breaking Q4 revenue and earnings but forecast lower Q1 sales than expected due to new regulations in India.

Honeywell (NYSE:HON) beat estimates with its earnings and forecast 2019 sales and profit largely above Wall Street projections party due to strong demand for aircraft parts.

Deutsche Bank (NYSE:DB) posted its first annual profit in four years but that was overshadowed by a weaker than expected Q4 as speculation persists the German government may step in to force a merger with German rival Commerzbank.

MARKETS

The TSX and U.S. equity futures are modestly higher after U.S. non-farm payrolls in December jumped 304,000, well ahead of the

165,000 expected indicating continued strength in the labour market.

The TSX capped off its most stellar month since May 2009 with a surge of 8.5% with only three negative sessions during January.

CURRENCIES

The Canadian dollar is flat at \$0.7622 (U.S).

COMMODITIES

West Texas Intermediate is up by 0.5% to \$54.06 a barrel,

Gold is flat at \$1,324.60 an ounce .

Daily Update

Sponsor content

We've posted the [podcast version](#) of our interview with *Adam Cegielski*, CEO of *Eyecarrot Innovations (TSXV:EYC)*. He explains how the company's Binovi technology is disrupting the vision care market...

...details the firm's growth estimates...

...and discusses how *Bryce Salvador* went from missing an NHL season due to concussion-related vision problems to Stanley Cup winner after getting treated with Binovi's vision

therapy.

Salvador is now an adviser to Eyecarrot.

A reminder to take a look at the new [*Capital Ideas Digest*](#) for new research on an unheralded company with a 10-year track record of revenue and earnings growth that can continue to reward shareholders.

Please email questions, comments or concerns to:

[*customercare@capitalideasresearch.com*](mailto:customercare@capitalideasresearch.com)

Access, ideas and insight.

[**Mark Bunting**](#)
Publisher,
[**Capital Ideas Media**](#)

www.capitalideasmedia.com





The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

Copyright © 2016 Capital Ideas Research, All rights reserved.

You are receiving this email because you are part of our investment network.

[Add us to your address book](#)

[unsubscribe from this list](#) [update subscription preferences](#)

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada